Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd R Burmester

Showing results (141-150 of 335) with videos related to

Pageof 34
Sort By:
RMD Open|June 3, 2025
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular diseaseGerd R Burmester, Eduardo Mysler, Peter Taylor, et al.
European Journal of Immunology|July 7, 2018
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursorsTobias Alexander, Qingyu Cheng, Jens Klotsche, et al.
Annals of the Rheumatic Diseases|March 12, 2018
Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)Désirée van der Heijde, David I Daikh, Neil Betteridge, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2018
Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)Désirée van der Heijde, David I Daikh, Neil Betteridge, et al.
Arthritis and Rheumatism|April 29, 2006
Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndromeThomas Egerer, Lorena Martinez-Gamboa, Anja Dankof, et al.
Arthritis Research & Therapy|March 13, 2012
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expressionDaniela Frölich, Daniela Blassfeld, Karin Reiter, et al.
Journal of Periodontology|March 1, 2016
Increased Periodontal Attachment Loss in Patients With Systemic SclerosisNicole Pischon, Daniela Hoedke, Sven Kurth, et al.
Rheumatology (Oxford, England)|September 11, 2021
Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritisGerd R Burmester, Vivian P Bykerk, Maya H Buch, et al.
RMD Open|September 1, 2025
To optimise the diagnostic process of rheumatic diseases affecting the hands using fluorescence optical imaging (FOI)Nele Stumper, Jörn Berger, Jens Klotsche, et al.
RMD Open|July 3, 2021
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Jacqueline Detert, Rolf Rau, et al.
Pageof 34

Showing results (141-150 of 335) with videos related to

Sort By:
Pageof 34
RMD Open|June 3, 2025
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular diseaseGerd R Burmester, Eduardo Mysler, Peter Taylor, et al.
European Journal of Immunology|July 7, 2018
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursorsTobias Alexander, Qingyu Cheng, Jens Klotsche, et al.
Annals of the Rheumatic Diseases|March 12, 2018
Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)Désirée van der Heijde, David I Daikh, Neil Betteridge, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2018
Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)Désirée van der Heijde, David I Daikh, Neil Betteridge, et al.
Arthritis and Rheumatism|April 29, 2006
Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndromeThomas Egerer, Lorena Martinez-Gamboa, Anja Dankof, et al.
Arthritis Research & Therapy|March 13, 2012
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expressionDaniela Frölich, Daniela Blassfeld, Karin Reiter, et al.
Journal of Periodontology|March 1, 2016
Increased Periodontal Attachment Loss in Patients With Systemic SclerosisNicole Pischon, Daniela Hoedke, Sven Kurth, et al.
Rheumatology (Oxford, England)|September 11, 2021
Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritisGerd R Burmester, Vivian P Bykerk, Maya H Buch, et al.
RMD Open|September 1, 2025
To optimise the diagnostic process of rheumatic diseases affecting the hands using fluorescence optical imaging (FOI)Nele Stumper, Jörn Berger, Jens Klotsche, et al.
RMD Open|July 3, 2021
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Jacqueline Detert, Rolf Rau, et al.
Pageof 34